Clinical trial · Interventional
Efficacy Study for Postoperative Chemoradiation Using Triweekly Cisplatin in Cervical Cancer Patients
Phase II Clinical Trial for Adjuvant Concurrent Chemoradiation Therapy in Post-operative Cervical Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): A competing trial has been initiated.
Summary
Brief summary (as posted)
The standard postoperative treatment for patients with cervical cancer who had high-risk factors is chemoradiation. Generally, weekly cisplatin or 5FU+cisplatin every 3 week have been used as chemotherapy regimens of chemoradiation. Based on their experience, the investigators hypothesized that tri-weekly cisplatin could be superior to weekly cisplatin. Therefore, the investigators are going to perform the efficacy study of postoperative, tri-weekly cisplatin chemoradiation for patients with cervical cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Neoplasms | Cervical Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| tri-weekly cisplatin | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- tri-weekly cisplatin
- description
- Patients in this arm will postoperatively receive cisplatin 75mg/m2 intravenously every 3 weeks, 3 cycles with radiation
- interventionNames
- Radiation: tri-weekly cisplatin
Primary outcomes (1)
- measure
- disease-free survival
- timeFrame
- 2 year
Secondary outcomes (4)
- measure
- overall survival
- timeFrame
- 2 year
- measure
- disease-free survival
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * cervical cancer * underwent radical hysterectomy * non-small cell type * FIGO stage 1B - 2A * have one or more risk factors (lymph node involvement, resection margin involvement, parametrial involvement) * GOG performance status 0 - 2 Exclusion Criteria: * Previous history of chemotherapy or radiation * History of other cancer * Hypersensitivity to platinum agents * Pregnancy * Serious medical disease
References
Publications (0)
Data not yet available